Back to results
US 7,964,571 B2Granted
Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
AssigneeEgen, Inc.
InventorsJason G. Fewell, Majed Matar, Jennifer Rice, Danny H. Lewis, Khursheed Anwer
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.
Claims37
A combination therapy for the treatment of a solid primary or metastasized tumor in a subject, comprising:
- administering a pharmaceutical composition to the subject, wherein the administering is intraperitoneal for treatment of tumors originated in or metastasized to the peritoneal cavity, peritumoral, or intratumoral, said pharmaceutical composition comprising a DNA plasmid that encodes interleukin-12 and a lipopolymer, said lipopolymer including a polyethylenimine backbone wherein cholesterol is covalently linked to the polyethylenimine backbone and polyethylene glycol is covalently linked to the polyethylenimine backbone and interleukin-12 is expressed;
- and administering at least one chemotherapeutic or anticancer agent to the subject, wherein said combination therapy results in inhibition of tumors.
A therapy for the treatment of a solid primary or metastasized tumor in a subject, comprising:
- administering a pharmaceutical composition to the subject, wherein the administering is intraperitoneal for treatment of tumors originated in or metastasized to the peritoneal cavity, peritumoral, or intratumoral, said pharmaceutical composition comprising a DNA plasmid that encodes interleukin-12 and a lipopolymer, said lipopolymer including a polyethylenimine backbone wherein cholesterol is covalently linked to the polyethylenimine backbone and polyethylene glycol is covalently linked to the polyethylenimine backbone, wherein expression of interleukin-12 results in inhibition of tumors.
Dependencies are inferred from the claim text.